Macrolide treatment for COVID-19

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), broke out in late 2019 to become a serious global threat to human health. The recent, rapid development of vaccines against COVID-19 represents a huge achievement and offers hope of ending the global pandemic. However, only a fraction of the world population can receive vaccines as of yet. As a result, large numbers of people continue to be exposed and become infected. Therefore, finding effective and low-priced drugs against COVID-19 and carrying out clinical trials of these drugs remain a worthwhile and beneficial pursuit.

Keywords

• macrolide treatment
• covid-19
• vaccines